Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$23.82
▼ $0.13 (-0.5%)
Market data updated: 09/18 01:28 PM
Fundamentals updated: 09/18/2026
News analyzed: 09/18/2026
Market Cap
$1.01B
Day Range
$23.50 - $24.18
52-Week Range
$16.65 - $29.52
Beta
—
Next Earnings
04.11.2026
AMPH is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-11.7% (1Y)
Strengths: 17/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $41.48 vs. price $23.82 (+74.1%)
Fair Value
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: -0.27 (3y annualized return -19.8% / max drawdown 73.4%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
as of 09/10/202669
This Week
69
7D Ago
→ 0
Stable
Technical
92
7D Ago: 94
→ -2
Fundamental
68
7D Ago: 68
→ 0
Growth
26
7D Ago: 26
→ 0
Valuation
67
7D Ago: 67
→ 0
News
100
7D Ago: 100
→ 0
Quality
58
7D Ago: 58
→ 0
Risk
48
7D Ago: 48
→ 0
Biggest Declines
📊 Score History
69
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
⚖️ Base Case
69 / 100
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of September 10, 2026
Then
69
$23.04
Now
69
$23.82
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
26
Quality
58
Value
67
Momentum
92
Risk
48
Sentiment
100
Fundamental
68
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Amphastar Pharmaceuticals has primarily focused on its stock performance and financial outlook. Analysts highlight its valuation as attractive, citing strong earnings as a key driver. The company was mentioned in discussions about generic drug stocks amid industry trends, with Barclays raising its price target to $23 while maintaining an equalweight rating. Additionally, Amphastar’s Q2 earnings call drew attention, though no specific results were detailed. The company’s inclusion in broader healthcare stock analyses underscores its position in the generic pharmaceutical sector.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Amphastar Pharmaceuticals, Inc.. News trend score: 100. Reason: 12 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
33
🎯 Conviction (vs. Emotion)
40
Psychology
52
Fundamentals
68
Technical
92
Valuation
67
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+27%
Market Narrative
58
Fundamental Reality
40
Narrative Gap
+18
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
AMPH’s psychology is dominated by **herding**, as peers underperformed today while the stock lagged further, consistent with relative weakness and crowd-driven underreaction. **Euphoria** and **confirmation bias** persist due to extreme positive sentiment, momentum, and a widening narrative gap despite weak fundamentals. **Anchoring** may keep traders near resistance, while **overconfidence** stems from momentum decoupling from earnings growth. The key question: *Will the narrative gap close, or will fundamentals force a re-evaluation?*
Updated: 09/06/2026, 03:02 PM
What could change this?
👥 What the crowd believes
"Barclays adjusted price target on Amphastar to $23 from $20"
"3 Generic Drug Stocks to Watch Amid Improving Industry Trends"
"Top 5 Analyst Questions From Amphastar’s Q2 Earnings Call"
"Portfolio Expansion and Pipeline Progress Drive Results"
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 86/100
🔴 Weakest match
Samuel Armstrong Nelson — 12/100
🗣️ Why do they disagree?
Based on their documented principles, the model estimates that Walter Bagehot’s strong liquidity score (86) and Benjamin Graham’s defensive rating (85) view the stock favorably, emphasizing financial resilience and value safety. Jesse Livermore’s positive trend score (77) also suggests a bullish tilt, whereas Graham’s enterprising score (64) and Howard Marks (59) indicate only modest discounts and caution about already‑high expectations. Mid‑range scores from Charles Mackay, Jack Schwager and Gerald Loeb (in the low‑50s) reflect mixed or neutral signals, showing no clear edge. Lower scores from the efficient‑market view (41), Edgar Lawrence Smith (34), Marks’s market‑cycle lens (33), Philip Fisher (30), Thorstein Veblen (28), Peter Lynch (26), Morgan Housel (24) and Samuel Armstrong Nelson (4) highlight concerns about stability, growth quality, market efficiency and overbought conditions, leading those frameworks to be skeptical. Consequently, the divergence arises from each methodology’s core focus—liquidity and defensive value versus growth quality, market timing and cycle risk.
Walter Bagehot
Lombard Street (1873)
🟢 86
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 85
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 76
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 64
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 59
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 57
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 52
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 42
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 42
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 34
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 30
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 28
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 26
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 25
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 12
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (11 bullish · 1 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
49.5%
Operating Margin
19.5%
Net Margin
13.6%
EBITDA Margin
19.5%
ROE
12.4%
ROA
6.0%
ROIC
—
EPS
$2.10
Cash
$170.18M
Total Debt
$619.71M
Current Ratio
4.02
Debt/Equity
0.79
How is Fair Value calculated? →
Current Price
$23.82
Estimated Fair Value (DCF)
$41.48
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+74.1%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
13.7%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 13.7% | $137.83M | $126.45M |
| 2 | 10.9% | $152.85M | $128.65M |
| 3 | 8.1% | $165.23M | $127.59M |
| 4 | 5.3% | $173.98M | $123.25M |
| 5 | 2.5% | $178.33M | $115.90M |
Base FCF (last actual year)
$121.23M
Terminal Value
$2.81B
Present Value of Terminal Value
$1.83B
Enterprise Value
$2.45B
Net Debt
$449.53M
Equity Value
$2.00B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$16.36
Tangible Book Value per Share (Tangible NAV)
$5.23
Sentiment based on basic keywords (not AI) — 12 positive, 8 neutral, 0 negative out of the last 20 articles.
Yahoo · 17.9.2026
Yahoo · 6.9.2026
Simply Wall St. · 6.9.2026
Yahoo · 5.9.2026
Simply Wall St. · 5.9.2026
Yahoo · 1.9.2026
StockStory · 1.9.2026
Yahoo · 1.9.2026
PR Newswire · 1.9.2026
Yahoo · 31.8.2026
Zacks · 31.8.2026
Yahoo · 27.8.2026
Zacks · 27.8.2026
Yahoo · 27.8.2026
StockStory · 27.8.2026
Benzinga · 24.8.2026
MT Newswires · 18.8.2026
StockStory · 15.8.2026
Zacks · 14.8.2026
Motley Fool · 14.8.2026
Amphastar Pharmaceuticals, Inc. (AMPH) currently has a StockIQ AI score of 69/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
AMPH currently scores 69/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, AMPH's estimated fair value is $41.48, which is 74.1% above the current price of $23.82. This is one valuation model among several signals in the fair-value category, not a price target.
AMPH's technical score is 92/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $41.48 vs. price $23.82 (+74.1%); Operating margin is stable or improving over time; Current ratio: 4.02.
Based on the real signals StockIQ computed: Calmar: -0.27 (3y annualized return -19.8% / max drawdown 73.4%); Revenue growth (last year): -1.7%; Earnings per share (EPS) growth: -33.7%.
StockIQ has no recorded dividend payment history for AMPH.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 4 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Zhou Rong | Open Market Sale | 2.9.2026 | 3,187 | -3,187 | $23.63 |
| PRINS RICHARD K | Open Market Sale | 11.8.2026 | 7,973 | -7,973 | $20.30 |
| PETERS WILLIAM J | Exercise of Derivative Securities | 7.8.2026 | 181,026 | +5,053 | $19.79 |
| PETERS WILLIAM J | Exercise of Derivative Securities | 7.8.2026 | 0 | -5,053 | — |
| PETERS WILLIAM J | Open Market Sale | 7.8.2026 | 172,846 | -8,180 | $22.48 |
| PETERS WILLIAM J | Exercise of Derivative Securities | 7.8.2026 | 5,053 | -5,053 | — |
| PETERS WILLIAM J | Exercise of Derivative Securities | 7.8.2026 | 5,053 | +5,053 | $19.79 |
| PETERS WILLIAM J | Open Market Sale | 7.8.2026 | 8,180 | -8,180 | $22.48 |
| Pierce Anthony T | Grant/Award from Employer | 9.7.2026 | 7,886 | +7,886 | — |
| Pierce Anthony T | Grant/Award from Employer | 9.7.2026 | 16,646 | +16,646 | — |
| Pierce Anthony T | Grant/Award from Employer | 9.7.2026 | 16,646 | +16,646 | — |
| Pierce Anthony T | Grant/Award from Employer | 9.7.2026 | 7,886 | +7,886 | — |
| Lee Howard | Tax Withholding in Shares | 2.6.2026 | 159,350 | -769 | $18.45 |
| Lee Howard | Tax Withholding in Shares | 2.6.2026 | 769 | -769 | $18.45 |
| Gerst Diane G. | Grant/Award from Employer | 1.6.2026 | 17,365 | +17,365 | — |
| PRINS RICHARD K | Grant/Award from Employer | 1.6.2026 | 17,365 | +17,365 | — |
| Gaugh David Russell | Grant/Award from Employer | 1.6.2026 | 14,447 | +8,143 | — |
| Lee Howard | Grant/Award from Employer | 1.6.2026 | 17,365 | +17,365 | — |
| ZASLOFF MICHAEL A | Grant/Award from Employer | 1.6.2026 | 17,365 | +17,365 | — |
| Deflin Gayle | Grant/Award from Employer | 1.6.2026 | 19,057 | +8,143 | — |
| Deflin Gayle | Grant/Award from Employer | 1.6.2026 | 17,365 | +17,365 | — |
| ZASLOFF MICHAEL A | Grant/Award from Employer | 1.6.2026 | 37,667 | +8,143 | — |
| Gaugh David Russell | Grant/Award from Employer | 1.6.2026 | 17,365 | +17,365 | — |
| PRINS RICHARD K | Grant/Award from Employer | 1.6.2026 | 37,598 | +8,143 | — |
| Gerst Diane G. | Grant/Award from Employer | 1.6.2026 | 31,899 | +8,143 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
5,134,473 shares short as of 2026-08-31 · vs. 4,928,331 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
68.2% of trading volume this week was short selling, vs. 69.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology